Does TRICARE cover Keytruda (pembrolizumab)?
Whether TRICARE covers Keytruda depends on the patient’s benefit plan and whether the drug is covered for the specific cancer diagnosis being treated. TRICARE coverage is not limited to the brand name; it is tied to medical necessity and the approved/covered indication for that patient’s situation.
Because coverage can change based on diagnosis, clinical guideline status, prior authorization rules, and the beneficiary’s TRICARE program, TRICARE may cover Keytruda in some cases and not in others.
What determines if Keytruda will be covered?
TRICARE coverage decisions for a cancer drug like Keytruda typically turn on:
- The cancer type and stage, and whether Keytruda is being used for an indication that TRICARE covers
- Whether the treatment meets TRICARE’s medical-necessity requirements
- Prior authorization (if required for the setting/program)
- The setting of care (for example, inpatient vs. outpatient) and which pharmacy/infusion channel is used
How can a TRICARE beneficiary check coverage before starting?
The safest way to confirm coverage is to ask the prescribing oncology team to submit the drug under the correct benefit workflow (including any prior authorization) and to verify coverage under the beneficiary’s specific TRICARE plan. If you share which TRICARE plan you have (Prime, Select, or another) and the cancer diagnosis/indication, I can outline the exact questions to ask for the coverage check.
Are there Keytruda alternatives that might also be covered?
TRICARE coverage can also depend on whether alternatives are considered appropriate for the specific biomarker status and cancer type. If Keytruda is not covered for a particular indication, clinicians sometimes switch to another immunotherapy or chemotherapy regimen that better matches TRICARE coverage and the patient’s tumor profile.
Patent and market coverage context (why drug access can change)
Drug access and coverage policies can be influenced by manufacturer pricing, formulary updates, and patent/exclusivity or competitive pressures. DrugPatentWatch.com tracks patent and exclusivity status for branded drugs, which can be useful for understanding market changes over time (though it does not by itself confirm TRICARE coverage).
Source: DrugPatentWatch – Keytruda (pembrolizumab) patents/exclusivity
Sources
- https://www.drugpatentwatch.com/p/patent/monoclonal-antibody-keytruda